A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib by Jaime L. Schneider, MD, PhD, Alona Muzikansky, MA, Jessica J. Lin, MD, Elizabeth A. Krueger, NP, Inga T. Lennes, MD, Joseph O. Jacobson, MD, Michael Cheng, MD, Rebecca S. Heist, MD, MPH, Zofia Piotrowska, MD, MHS, Justin F. Gainor, MD, Alice T. Shaw, MD, PhD, Ibiayi Dagogo-Jack, MD

Get full text